EXPERIENCE IN APPLICATION OF TOCILIZUMAB AT SYSTEM VARIANT OF JUVENILE IDIOPATHIC ARTHRITIS IN THE REPUBLIC OF BASHKORTOSTAN

Background: To summarize the experience in application of tocilizumab at system variant of juvenile idiopathic arthritis in the Republic of Bashkortostan. Patients and methods: In cardiorheumatologic department of Republican Pediatric Clinical Hospital of Ufa there were 9 children (6 boys and 3 girls) aged from 2,5 to 13,8 years (middle age — 8,2 years) under supervision. Middle age in a disease onset made 4,5 years. All patients were exposed to the combined antirheumatic therapy before prescription of tocilizumab. Despite the therapy, the patients still had a high degree of activity of a disease that was the basis for prescription of tocilizumab. The average single dose of a preparation made 11,2 mg/kg for children with body weight under 30 kg, 8,7 mg/kg for children over 30 kg. Results: 8 children were exposed to the continuous therapy with tocilizumab, therapy duration fluctuated from 6 to 52 (on the average 17,8) months. Treatment was stopped at 1 patient because of insufficient effect and at 1 patient because of the development of the undesirable phenomena. The minimum improvement defined as achievement of ACR_pedi30 criterion was reached in all patients throughout the entire period of treatment by the preparation. The prescription of tocilizumab allowed to stop the system manifestations of a disease within 1 month of treatment in all children. The JADAS-27 index decreased twice (from 33,6 to 16,5) in 1 month from the beginning of the therapy. From the 3rd month of treatment all patients showed the normalization of indicators of the peripheral blood characterizing the activity of inflammatory process (ESR, contents of leukocytes and haemoglobin, SRP serumal level). In 3 and 6 months from the therapy beginning 7 patients reached 50%, and 5 and 6 — 70% improvement, respectively. Two children didn't reach 70% improvement in view of remaining insignificant or moderately active articulate syndrome. Conclusion: The analysis of the research results showed high efficiency of tocilizumab concerning system manifestations and activity of inflammatory process. At the same time 3 patients still suffered the moderate articular syndrome in the form of persistent oligoarthritis, 1 patient — in the form of polyarthritis.

1. Cassidy J., Petty R., Laxer R. M., Lindsley C. B. Textbook of Pediatric Rheumatology. 6th ed. Elsevier. 2011. 794 p.

2. Malievskii V. A. Yuvenil’nye artrity: epidemiologiya, medikosotsial’nye i ekonomicheskie posledstviya, kachestvo zhizni. Avtoref. dis. … dokt. med. nauk [Juvenile Arthritis: Epidemiology, MedicoSocial and Economic Consequences, Quality of Life Rate. Author’s abstract]. Moscow, 2006. 38 p.

3. Petty R. E., Southwood T. R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic rthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.

4. Fantini F. Classification of chronic arthritides of childhood (juvenile idiopathic arthritis): criticism and suggestions to improve the efficacy of the Santiago — Durban criteria. J. Rheumatol. 2001; 28: 456–459.

5. Thomas E., Barrett J. H., Donn R. et al. Subtyping of juvenile idiopathic arthritis using latent class analysis. Arthritis Rheum. 2000; 43 (7): 1496–1503.

6. Hofer M. F., Mouy R., Prieur A.-M. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J. Rheumatol. 2000; 28: 1083–1090.

7. Merino R., De Inocencio J., Garcia-Consuegra J. Evaluation of the ILAR classification criteria for juvenile idiopathic arthritis in Spanish children. J. Rheumatol. 2001; 12: 2731–2736.

8. Krumrey-Langkammerer M., Hafner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J. Rheumatol. 2001; 28: 2544–2547.

9. Lomater C., Gerloni V., Gattinara M., Mazzotti J., Climaz R., Fantini F. Systemic onset iuvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27 (2): 491–496.

10. Malievskii V. A. Sistemnyi variant yuvenil’nykh artritov: techenie i iskhody [Constitutional Juvenile Arthritis: Progress and Outcome]. Mat-ly V Vseros. konf. «Sistemnye revmaticheskie bolezni i spondiloartrity» (Proceedings of 5 th Russian National Conference “Constitutional Rheumatic Diseases and Spondylarthritis”). Moscow, 2010.

11. Rose-John S., Scheller J., Elson G. et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 2006; 80: 227–236.

12. De Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G. R., Martini A. Correlation of interleukin-6 levels with joint involvement and thrombocytosis in patients with systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.

13. de Benedetti F., Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 687–693.

14. Lieskovska J., Guo D., Derman E. Growth impairment in IL-6- overexpressing transgenic mice is associated with induction of SOCS3 mRNA. Growth Horm. IGF Res. 2003; 13: 26–35.

15. Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.

16. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A., Wright S., Calvo I. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367: 2385–2395.

17. De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): 2-year data from tender, a phase 3 clinical trial. Ann. Rheum. Dis. 2012; 71 (Suppl. 3): 425.

18. Baranov A. A., Alekseeva E. I., Denisova R. V., Valieva S. I., Bzarova T. M., Isaeva K. B., Sleptsova T. V., Mitenko E. V., Chistyakova E. G., Fetisova A. N. Vopr. sovr. pediatrii — Current pediatrics. 2013; 12 (2): 26–34.

19. Alekseeva E., Denisova R., Valieva S. Tocilizumab therapy in children with systemic juvenile idiopathic arthritis. Russian experience. Ann. Rheum. Dis. 2013; 72 (Suppl. 3): 736.

20. Consolaro A., Ruperto N., Bazso F., Pistorio A., Magni-Manzoni S., Filocamo G., Malattia C., Viola S., Martini A., Ravelli A. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthr. Care & Res. 2009; 61 (5): 658–666.

21. Kuz’mina N. N., Nikishina I. P., Shaikov A. V. etc. Nauch.-prakt. revmatol — Reseach and practical rheumatology. 2002; 1: 40–47.

22. Postanovlenie Pravitel’stva Respubliki Bashkortostan № 540 ot 30.12.2011 g. «O predostavlenii mer sotsial’noi podderzhki otdel’nym gruppam naseleniya v obespechenii lekarstvennymi preparatami i izdeliyami meditsinskogo naznacheniya pri okazanii ambulatorno-poliklinicheskoi pomoshchi» [Governmental Regulation of the Republic of Bashkortostan № 540 “Social Safety Net for Certain Population Groups: Supplying Medicines, Medical Devices along with Outpatient Care” dated 30 December 2011]. Ufa, 2011.

23. Postanovlenie Pravitel’stva Respubliki Bashkortostan № 218 ot 28 maya 2013 g. «O predostavlenii mer sotsial’noi podderzhki otdel’nym gruppam naseleniya v obespechenii lekarstvennymi preparatami i izdeliyami meditsinskogo naznacheniya pri okazanii ambulatorno-poliklinicheskoi pomoshchi» [Governmental Regulation of the Republic of Bashkortostan № 218 “Social Safety Net for Certain Population Groups: Supplying Medicines, Medical Devices along with Outpatient Care” dated 28 May 2013]. Ufa, 2013.

24. Postanovlenie Pravitel’stva Respubliki Bashkortostan № 291 ot 28 iyunya 2013 g. «O vnesenii izmenenii v Programmu gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi v Respublike Bashkortostan na 2013 god i na planovyi period 2014 i 2015 godov» [Governmental Regulation of the Republic of Bashkortostan № 291 “Introduction of Amendments to the State Guarantee Programme of Free Medical Care in 2013 and Target Period of 2014–2015” dated 28 June 2013]. Ufa, 2013.

25. Prikaz MZ RF № 777-n ot 9 noyabrya 2012 g. «Ob utverzhdenii standarta okazaniya pervichnoi mediko-sanitarnoi meditsinskoi pomoshchi detyam pri yunosheskom artrite s sistemnym nachalom» [Directory of the Ministry of Healthcare № 777-n “Standards of Emergency Medical Care in Children with Adolescent Constitutional Arthritis” dated 9 November 2012].Moscow, 2012.

26. Prikaz MZ RF № 668-n ot 7 noyabrya 2012 g. «Ob utverzhdenii standarta okazaniya spetsializirovannoi meditsinskoi pomoshchi detyam pri yunosheskom artrite s sistemnym nachalom» [Directory of the Ministry of Healthcare № 668-n “Standards of Medical Care in Children with Adolescent Constitutional Arthritis” dated 7 November 2012].Moscow, 2012.

27. Baranov A. A., Alekseeva E. I., Bzarova T. M., Valieva S. I., Denisova R. V., Isaeva K. B., Karagulyan N. A., Litvitskii P. F., Mitenko E. V., Sleptsova T. V., Fetisova A. N., Chistyakova E. G., Taibulatov N. I., Morev S.Yu. Vopr. sovr. pediatrii — Current pediatrics. 2013; 12 (1): 2–16.